FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 79631 - Cures Acceleration Network Review Board - Statutory (Congress Created)

GENERAL INFORMATION

Committee Name	Cures Acceleration Network Review Board	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	79631
Original Establishment Date	1/4/2012	Committee Status	Chartered
Actual Termination Date		Committee URL	https://ncats.nih.gov/advisory/canboard/roster
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	29
Terminated This FY	No	Designated Fed Officer Position Title*	Director, Office of Grants Management and Scientific Review
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	2/7/2024	Designated Federal Officer First Name*	ANNA
Date Of Renewal Charter	2/7/2026	Designated Federal Officer Middle Name	L.
Projected Termination Date		Designated Federal Officer Last Name*	RAMSEY-EWING
Exempt From Renewal*	No	Designated Federal Officer Suffix	PHD
Specific Termination Authority		Designated Federal Officer Phone*	(301) 435-0809
Establishment Authority*	Statutory (Congress Created)	Designated Federal Officer Fax*
Specific Establishment Authority*	42 U.S.C. 287a(d)	Designated Federal Officer Email*	anna.ramseyewing@nih.gov
Effective Date Of Authority*	3/23/2010
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Continue
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	This committee is composed of highly qualified scientists and public representatives with expertise related to the interests of the Center. It provides a breadth and balance of specialized knowledge necessary to assess the long-range goals, program concepts, research opportunities, and direction of ongoing research and future plans.
How is membership balanced?*	The Cures Acceleration Network Review Board, NCATS, consists of 24 appointed members who were selected based on the following requirements: (1) for each of the fields of (a) basic research, (b) medicine, (c) biopharmaceuticals, (d) discovery and delivery of medical products, (e) bioinformatics and gene therapy, (f) medical instrumentation, and (g) regulatory review and approval of medical products, the Secretary will select at least 1 individual who is eminent in such fields; (2) at least 4 individuals will be recognized leaders in professional venture capital or private equity organizations and have demonstrated experience in private equity investing; and (3) at least 8 individuals will represent disease advocacy organizations. In addition, the Secretary will appoint as ex officio members of the Board (1) a representative of the NIH, recommended by the Secretary; (2) a representative of the Office of the Assistant Secretary of Defense for Health Affairs, recommended by the Secretary of Defense; (3) a representative of the Office of the Under Secretary for Health for the Veterans Health Administration, recommended by the Secretary of Veterans Affairs; (4) a representative of the National Science Foundation, recommended by the Chair of the National Science Board; and (5) a representative of the Food and Drug Administration, recommended by the Commissioner of Food and Drugs.
How frequent & relevant are cmte mtgs?*	The CANRB did not have enough members to constitute a quorum and did not meet in FY 2025. As soon as the required quorum can be met in FY26, the Board will attempt to convened 4 times. The CAN Review Board remains relevant to provide advice on a subset of NCATS programs.
Why advice can't be obtained elsewhere?*	This committee is composed of recognized experts in basic research, medicine, biopharmaceuticals, discovery and delivery of medical products, bioinformatics and gene therapy, medical instrumentation, and regulatory review and approval of medical products. There are also members who are recognized leaders in professional venture capital or private equity organizations with demonstrated experience in private equity investing, and members who represent disease advocacy organizations. Their recommendations cannot be obtained from other sources because the complex nature of research requires a specialized balance and breadth of objective expertise not otherwise available.
Why close or partially close meetings?	N/A
Recommendation Remarks	Reports: This committee did not produce any reports this reporting period. The DFO and Decision Maker are the same person, the Director, Office of Grants Management and Scientific Review, based on the assignment of duties within the Center. The Charter allows the Committee to have 29 authorized members including but not limited to SGEs, Ex-Officios, and Representatives (if applicable). There are currently appointed SGEs and Ex-Officios, and though there can be four appointed Representatives, there are no appointed Representatives in this time period. Although the committee is authorized up to 24 members, the committee will operate with less members due to delays in the identification and appointment of new members. Four Ex-Officios have rotated off during this time period; Dr. Tabak rotated off 11/08/2023, Drs. Dickinson and Ramoni rotated off 2/29/2024, and Weichold rotated off 02/28/2024. Dr. Bertagnolli became an Ex Officio on 11/09/2023 and has been appointed to serve until 01/20/2025. The CANRB did not have enough members to constitute a quorum and did not meet in FY 2025. As soon as the required quorum can be met in FY26, the Board will be try to convened 4 times. The CAN Review Board remains relevant to provide advice on a subset of NCATS programs. No Ex Officio members conducted any work for the committee in FY2025. There is no chair for this committee, therefore, there is no chair listed in this report. There are no Representatives in this committee, so none are listed in this report. Three members, Ms. Ruediger, Ms. Schill and Dr. Summar were administratively extended to 04/28/2024

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	No	Action Reorganize Priorities*	No
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	No	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	No	Action Other	Yes
Outcome Increased Customer Satisfaction	No	Action Comment	The Committee advises and provides recommendations to the NCATS director on the policies, programs and procedures for carrying out the duties of the Office of the Director and on identifying significant barriers to successful translation of basic science into clinical application.
Outcome Implement Laws/Reg Requirements	No	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	N/A	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new way to treat and prevent diseases.	Grants Review Comment	N/A
Number Of Recommendations*	66	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	There were no recommendations for FY2024	Access Agency Website	Yes
% of Recs Fully Implemented*	0.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	0.00%	Access Publications	No
% of Recs Partially Implemented Comment	Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.	Access Other	Yes
Agency Feedback*	Yes	Access Comment	IC Committee Management Officer 240-669-5201
Agency Feedback Comment*	Information is provided to the public at each meeting. The public can view information related to the Committee through the committee’s official website.	Narrative Description*	Authorized to reduce significant barriers to successful translation and accelerate the development of high-need cures, the Cures Acceleration Network (CAN) provides the National Center for Advancing Translational Sciences with flexibility in how it funds projects. This authority is guided by the CAN Review Board, which according to its charter, advises and provides recommendations to the NCATS director on the policies, programs and procedures for carrying out the duties of the Office of the Director and on identifying significant barriers to successful translation of basic science into clinical application.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*
10. Other Costs		10. Est. Other Costs Next FY*
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:41 AM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*		Est Cost Remarks
Cost Remarks

Interest Areas

Category Area Health Health Care Public Health Treatment

Custom Links

Committee Level Reports